Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45 th Annual Health Care Conference on March 4, ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer has agreed to pay $59,746,277.54 ... and honoraria payments to health care providers to encourage them to prescribe Nurtec ODT (Nurtec), a prescription medication for migraine treatment.

Pfizer's Q4 adjusted EPS was $0.63 ... This was primarily driven by legacy Seagen, Vyndaqel family, Eliquis, Nurtec ODT/Vydura, and Xtandi, partially offset by lower revenues for Abrysvo, Xeljanz ...

So were other acquired drugs, especially Nurtec ODT. Pfizer's cost-cutting efforts also paid off, with adjusted diluted earnings per share soaring more than 6x. Sure, Pfizer still faces patent ...

Nurtec ODT/Vydura sales jumped 39% to $392 million ... and Abrysvo RSV vaccine sales slumped 62% to $198 million. Guidance: Pfizer reaffirms 2025 revenues of $61 billion-$64 billion compared ...

Pfizer recently announced better-than-expected Q4 results. Products picked up with the acquisition of Seagen were big contributors to growth, including Adcetris and Padcev. So were other acquired ...

Pfizer Inc. (NYSE:PFE – Get Free Report ... and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs ...

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...